Sumitomo Pharma Wins Conditional Japan Approval for First iPS Cell-Derived Parkinson’s Therapy

Sumitomo Dainippon Pharma Co ( (JP:4506) ) just unveiled an announcement.

Sumitomo Pharma has received conditional and time-limited approval in Japan to manufacture and market AMCHEPRY, an allogeneic iPS cell-derived dopaminergic neural progenitor cell therapy for improving motor symptoms in Parkinson’s disease patients who do not respond adequately to existing drug treatments. The product, based on clinical data from Kyoto University Hospital and produced using technology sourced from CiRA Foundation, Kyoto University, and Eisai, is the world’s first iPS cell-derived regenerative medicine and has been granted both SAKIGAKE and orphan regenerative medical product designations.

Following reimbursement listing, Sumitomo Pharma will handle marketing, while S-RACMO will manufacture AMCHEPRY at its SMaRT facility, the first commercial-scale plant dedicated to allogeneic iPS cell-derived regenerative products. The company plans post-marketing clinical studies and surveillance to secure full approval, positioning the therapy as a new treatment option in Parkinson’s disease and reinforcing the Sumitomo group’s leadership ambitions in regenerative and cellular medicine.

The most recent analyst rating on (JP:4506) stock is a Hold with a Yen2077.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.

More about Sumitomo Dainippon Pharma Co

Sumitomo Pharma Co., Ltd. is a Japanese pharmaceutical company focused on developing and commercializing innovative therapies, including regenerative and cellular medicines, with a particular emphasis on central nervous system disorders such as Parkinson’s disease. RACTHERA Co., Ltd., a joint venture between Sumitomo Chemical and Sumitomo Pharma, leads regenerative and cellular medicine R&D within the Sumitomo Chemical Group, while S-RACMO serves as a CDMO specializing in process development and manufacturing of iPS cell-derived regenerative products.

Average Trading Volume: 11,641,824

Technical Sentiment Signal: Buy

Current Market Cap: Yen749.9B

Find detailed analytics on 4506 stock on TipRanks’ Stock Analysis page.